CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioNTech SE

BNTX
$25.18BLarge Cap

Next catalyst

Phase 3April 2027

BNT162b2

SARS-CoV-2 Infection

Get an email about BNTX's next catalysts

Track BioNTech (BNTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 7 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline

Catalyst Timeline

8 upcoming, 2 past

Phase 3Next

BNT162b2 Phase 3 Est. Readout

April 2027~BNT162b2700

Estimated primary completion for BNT162b2 trial (NCT07798648) in COVID-19 Vaccines. Topline data typically follows completion by weeks to months.

Source
Phase 2

PM8002 Phase 2 Est. Readout

May 2027~PM8002100

Estimated primary completion for PM8002 trial (NCT07133750) in CRC (Colorectal Cancer). Topline data typically follows completion by weeks to months.

Source
Phase 2

BNT166a Phase 2 Est. Readout

June 2027~BNT166a310

Estimated primary completion for BNT166a trial (NCT07379580) in Mpox (Monkeypox). Topline data typically follows completion by weeks to months.

Source
Phase 2

BNT327 Dose Level 1 (DL1) Phase 2 Est. Readout

June 2027~BNT327 Dose Level 1 (DL1)110

Estimated primary completion for BNT327 Dose Level 1 (DL1) trial (NCT06449209) in Extensive-stage Small-cell Lung Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 2

DB-1305/BNT325 Phase 2 Est. Readout

Q3 2027~QDB-1305/BNT3251,123

Estimated primary completion for DB-1305/BNT325 trial (NCT05438329) in Advanced Solid Tumor. Topline data typically follows completion by weeks to months.

Source
Phase 2

DB-1303/BNT323 Phase 2 Est. Readout

August 2027~DB-1303/BNT323796

Estimated primary completion for DB-1303/BNT323 trial (NCT05150691) in HER2-positive Advanced Solid Tumor. Topline data typically follows completion by weeks to months.

Source
Phase 3

Gotistobart Phase 3 Est. Readout (PRESERVE-003)

Q3 2027~QGotistobart630

Estimated primary completion for Gotistobart trial (NCT05671510) in Non Small Cell Lung Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 2

BNT3212 Phase 2 Est. Readout

November 2027~BNT3212375

Primary completion for BNT3212 trial (NCT07147348) in Advanced Solid Tumor

Source

How BNTX's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸EuropeMAINZ7.8K employees

BioNTech SE (/biːˈɒntɛk/ bee-ON-tek; or /baɪˈɒntɛk/ bye-ON-tek short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.

Website
Drug Pipeline

Pumitamig

Phase 3

Extensive-stage Small-cell Lung Cancer

BNT162b2

Phase 3

SARS-CoV-2 Infection

BNT113

Phase 3

Unresectable Head and Neck Squamous Cell Carcinoma

BNT162b1

Phase 3

SARS-CoV-2 Infection

BNT162b2 OMI

Phase 3

SARS-CoV-2 Infection

BNT162b2 (Omi XBB.1.5)

Phase 3

SARS-CoV-2 Infection

BNT162b5 Bivalent (WT/OMI BA.2)

Phase 3

SARS-CoV-2 Infection

Seasonal Inactivated Influenza Vaccine

Phase 3

SARS-CoV-2 Infection

Influenza and COVID-19 Combination A

Phase 3

Influenza

BNT162b2 (2025/2026 formulation)

Phase 3

COVID-19

BNT162b2.B.1.351

Phase 3

SARS-CoV-2 Infection

BNT162b2 (Omi LP.8.1)

Phase 3

COVID-19

Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose

Phase 3

SARS-CoV-2 Virus

Investigational Influenza Vaccine

Phase 3

Influenza,Human

Combination (Bivalent) BNT162b2 and BNT162b2 OMI

Phase 3

SARS-CoV-2 Infection

Combination BNT162b2 and BNT162b2 OMI

Phase 3

SARS-CoV-2 Infection

BNT162b2 Vaccine

Phase 3

COVID-19

BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)

Phase 3

COVID-19

BNT324

Phase 3

Advanced Lung Cancer

Prednisone/prednisolone

Phase 3

Metastatic Castration-resistant Prostate Cancer

Gotistobart

Phase 3

Non Small Cell Lung Cancer

DB-1303/BNT323

Phase 3

HER2-positive Breast Cancer

BNT323/DB-1303

Phase 3

Endometrial Cancer

BNT162b5 Bivalent (Original/OMI BA.4/BA.5)

Phase 3

SARS-CoV-2 Infection

BNT162b2 Bivalent (WT/OMI BA.4/BA.5)

Phase 3

SARS-CoV-2 Infection

Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose

Phase 3

SARS-CoV-2 Virus

Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose

Phase 3

SARS-CoV-2 Virus

BNT162b2 (Omi KP.2)

Phase 3

SARS-CoV-2 Infection

Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose

Phase 3

SARS-CoV-2 Virus

BNT162b2 Bivalent (WT/OMI BA.1)

Phase 3

SARS-CoV-2 Infection

BNT162b7 Bivalent (Original/OMI BA.4/BA.5)

Phase 3

SARS-CoV-2 Infection

Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose

Phase 3

SARS-CoV-2 Virus

BNT162b2SA

Phase 3

SARS-CoV-2 Infection

Carboplatin (or cisplatin if carboplatin is not tolerated)

Phase 3

Extensive-stage Small-cell Lung Cancer

Influenza and COVID-19 Combination B

Phase 3

Influenza

Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose

Phase 3

SARS-CoV-2 Virus

BNT162b2 (Omi JN.1)

Phase 3

SARS-CoV-2 Infection

Capox

Phase 3

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

BNT162b7 Monovalent (OMI BA.4/BA.5)

Phase 3

SARS-CoV-2 Infection

BNT162b6 Bivalent (Original/OMI BA.4/BA.5)

Phase 3

SARS-CoV-2 Infection

Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose

Phase 3

SARS-CoV-2 Virus

qIRV (22/23)

Phase 2

Influenza, Human

QIV

Phase 2

Influenza, Human

tIRV

Phase 2

Influenza, Human

BNT165c

Phase 2

Malaria

Nab-placlitaxel

Phase 2

Locally Advanced Breast Cancer

BNT317 DL2

Phase 2

Advanced Solid Tumor

Lopinavir and Ritonavir Tablets

Phase 2

Advanced Solid Tumors

SoC chemotherapy 1

Phase 2

Advanced Solid Tumor

BNT165d

Phase 2

Malaria

BNT3214

Phase 2

Advanced Solid Tumor Cancer

BNT327 Optimized Dose

Phase 2

Locally Advanced Breast Cancer

Obrixtamig

Phase 2

Extensive-stage Small Cell Lung Carcinoma

BNT327 Dose Level 1 (DL1)

Phase 2

Extensive-stage Small-cell Lung Cancer

BNT317 DL6

Phase 2

Advanced Solid Tumor

DB-1311

Phase 2

Advanced Solid Tumors

BNT317 DL1

Phase 2

Advanced Solid Tumor

DB-1305/BNT325

Phase 2

Advanced Solid Tumor

PM8002

Phase 2

CRC (Colorectal Cancer)

BNT317 DL5

Phase 2

Advanced Solid Tumor

BNT329

Phase 2

Advanced Solid Cancers

BNT326

Phase 2

Advanced Solid Tumor

BNT162b3

Phase 2

Covid-19

BNT111

Phase 2

Melanoma Stage III

Pertuzumab Injection

Phase 2

HER2-positive Advanced Solid Tumor

Autogene cevumeran

Phase 2

Advanced Melanoma

BNT314

Phase 2

Metastatic Colorectal Cancer

bivalent BNT162b2 (original/Omi BA.4/BA.5)

Phase 2

Influenza, Human

BNT162b2s01

Phase 2

COVID-19

DB-1311/BNT324

Phase 2

Solid Tumors

BNT327

Phase 2

Non-small Cell Lung Cancer

BNT142

Phase 2

Solid Tumor

BNT327 Equivalent Q3W Dose

Phase 2

Locally Advanced Breast Cancer

BNT3212

Phase 2

Advanced Solid Tumor

Monovalent BNT162b2 (B.1.1.529.1)

Phase 2

SARS-CoV-2 Infection

BNT317 DL3

Phase 2

Advanced Solid Tumor

SoC chemotherapy 2

Phase 2

Advanced Solid Tumor

RO7198457 intravenous (IV)

Phase 2

Colorectal Cancer Stage II

BNT317 selected DLA

Phase 2

Advanced Solid Tumor

BNT327 Dose Level 2 (DL2)

Phase 2

Extensive-stage Small-cell Lung Cancer

BNT166a

Phase 2

Monkeypox

BNT323

Phase 2

Locally Advanced Breast Cancer

Investigational COVID-19 Vaccine

Phase 2

Influenza

Monovalent BNT162b2 (B.1.1.7)

Phase 2

SARS-CoV-2 Infection

BNT165e

Phase 2

Malaria

COVID-19 Vaccine

Phase 2

Influenza,Human

Monovalent BNT162b2 (B.1.617.2)

Phase 2

SARS-CoV-2 Infection

BNT162a1

Phase 2

Infections, Respiratory

Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)

Phase 2

SARS-CoV-2 Infection

BNT164a1

Phase 2

Tuberculosis

BNT327 Dose Level 1 (DL2)

Phase 2

Locally Advanced Breast Cancer

BNT317 DL4

Phase 2

Advanced Solid Tumor

bIRV

Phase 2

Influenza, Human

Chemotherapy Regimen 3

Phase 2

CRC (Colorectal Cancer)

CA19-9-targeting monoclonal antibody

Phase 2

Advanced Solid Cancers

BNT162c2

Phase 2

Infections, Respiratory

Chemotherapy Regimen 2

Phase 2

CRC (Colorectal Cancer)

BNT317 selected DLB

Phase 2

Advanced Solid Tumor

Chemotherapy Regimen 1

Phase 2

CRC (Colorectal Cancer)

BNT164b1

Phase 2

Tuberculosis

Frequently asked questions

What is in BioNTech SE's drug pipeline?→

CatalystAlert tracks 100 drug candidates in BioNTech SE's (BNTX) pipeline across Phase 3, Phase 2. Its lead program is BNT162b2 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is BioNTech SE's next FDA catalyst?→

BioNTech SE's (BNTX) next tracked catalyst is a Phase 3 readout expected April 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track BNTX biotech catalysts?→

Add BNTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioNTech SE's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply